Validation Data Gallery
Filter:
Tested Applications
| Positive IHC detected in | human kidney tissue, human colon cancer tissue, human placenta tissue Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0 |
Recommended dilution
| Application | Dilution |
|---|---|
| Immunohistochemistry (IHC) | IHC : 1:50-1:500 |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
Published Applications
| KD/KO | See 2 publications below |
| WB | See 2 publications below |
| IF | See 1 publications below |
Product Information
16338-1-AP targets ABP1 in WB, IHC, IF, ELISA applications and shows reactivity with human samples.
| Tested Reactivity | human |
| Cited Reactivity | human |
| Host / Isotype | Rabbit / IgG |
| Class | Polyclonal |
| Type | Antibody |
| Immunogen | ABP1 fusion protein Ag9492 相同性解析による交差性が予測される生物種 |
| Full Name | amiloride binding protein 1 (amine oxidase (copper-containing)) |
| Calculated molecular weight | 751 aa, 85 kDa |
| Observed molecular weight | 85 kDa |
| GenBank accession number | BC014093 |
| Gene Symbol | ABP1 |
| Gene ID (NCBI) | 26 |
| RRID | AB_2878245 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Purification Method | Antigen affinity purification |
| UNIPROT ID | P19801 |
| Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol pH 7.3. |
| Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. |
Protocols
| Product Specific Protocols | |
|---|---|
| IHC protocol for ABP1 antibody 16338-1-AP | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
Publications
| Species | Application | Title |
|---|---|---|
Front Pharmacol Photodynamic Therapy of Novel Photosensitizer Ameliorates TNBS-Induced Ulcerative Colitis via Inhibition of AOC1.
| ||
Cancer Manag Res AOC1 Contributes to Tumor Progression by Promoting the AKT and EMT Pathways in Gastric Cancer.
|